| Patent application number | Description | Published |
|---|
| 20100314575 | ANTI-ICING SUPERHYDROPHOBIC COATINGS - Superhydrophobic coating compositions are provided. The compositions comprise nanoparticles between 5-100 nm in size and a polymeric binder. The compositions are effective in preventing ice formation on the surface of various substrates. | 12-16-2010 |
| 20110111656 | DURABLE SUPERHYDROPHOBIC COATINGS - Durable superhydrophobic coating composition having a composition ranging from about 10 to about 80 w.t. % of an acrylic polymer resin, from about 5 to about 40 w.t. % of a polysiloxane oil, from about 1 to about 50 w.t. % of hydrophobic particles, from about 0.1 to about 10 w.t. % metal oxides, and the remainder being one or more solvents and optionally other additives. Methods of making the coating, as well as coated substrates, are also provided. | 05-12-2011 |
| 20110303620 | Superoleophobic and Superhydrophilic Fabric Filters for Rapid Water-Oil Separation - Product, method of making product, and technique for using product to separate oil from water via a filter, such as cotton, polyester, or leather, coated with a chemical that blocks oil while allowing water to pass therethrough. | 12-15-2011 |
| Patent application number | Description | Published |
|---|
| 20100098634 | Imaging Agents Useful for Identifying AD Pathology - Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease. | 04-22-2010 |
| 20100317842 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry - The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents. | 12-16-2010 |
| 20110002850 | Nitro-Imidazole Hypoxia Imaging Agent - The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography. | 01-06-2011 |
| 20110046378 | Novel Imaging Agents for Detecting Neurological Dysfunction - Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease | 02-24-2011 |
| 20110091382 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION - Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease. | 04-21-2011 |
